Michael Scott Abers

Michael Scott Abers

Auto-generated profile, based on publicly available information

Michael Scott Abers

Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2019 in New England Journal of Medicine
Verified
Journal Article
Closed access
DMDaniel M Musher
Daniel M Musher
MAMichael S Abers
Michael S Abers
VCVicente F Corrales-Medina
Vicente F Corrales-Medina
Among patients who are hospitalized for pneumococcal pneumonia, the incidence of myocardial infarction is 7 to 8%. The true incidence of postinfection myocardial infarction may be higher than estimated, given the practice of attributing elevated troponin levels to “troponin leak.”

11 January 2021 in JCI Insight
Verified
Journal Article
Open access
PDF file
MAMichael S. Abers
Michael S. Abers
ODOttavia M. Delmonte
Ottavia M. Delmonte
EREmily E. Ricotta
Emily E. Ricotta
JFJonathan Fintzi
Jonathan Fintzi
DFDanielle L. Fink
Danielle L. Fink
LNLuigi Daniele Notarangelo
Luigi Daniele Notarangelo
Immune and inflammatory responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) contribute to disease severity of coronavirus disease 2019 (COVID-19). However, the utility of specific immune-based biomarkers to predict clinical outcome remains elusive. Here, we analyzed levels of 66 soluble biomarkers in 175 Italian patients with COVID-19 ranging from mild/moderate to critical severity and assessed type I IFN–, type II IFN–, and NF-κB–dependent whole-blood transcriptional signatures. A broad inflammatory signature was observed, implicating activation of various immune and nonhematopoietic cell subsets. Discordance between IFN-α2a protein and IFNA2 transcript levels in blood suggests that type I IFNs during COVID-19 may be primarily produced by tissue-resident cells. Multivariable analysis of patients’ first samples revealed 12 biomarkers (CCL2, IL-15, soluble ST2 [sST2], NGAL, sTNFRSF1A, ferritin, IL-6, S100A9, MMP-9, IL-2, sVEGFR1, IL-10) that when increased were independently associated with mortality. Multivariate analyses of longitudinal biomarker trajectories identified 8 of the aforementioned biomarkers (IL-15, IL-2, NGAL, CCL2, MMP-9, sTNFRSF1A, sST2, IL-10) and 2 additional biomarkers (lactoferrin, CXCL9) that were substantially associated with mortality when increased, while IL-1α was associated with mortality when decreased. Among these, sST2, sTNFRSF1A, IL-10, and IL-15 were consistently higher throughout the hospitalization in patients who died versus those who recovered, suggesting that these biomarkers may provide an early warning of eventual disease outcome.

27 September 2017 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
PDF file
DMDaniel M. Musher
Daniel M. Musher
MAMichael S Abers
Michael S Abers
JBJohn G Bartlett
John G Bartlett
Before 1945, Streptococcus pneumoniae caused more than 90% of cases of pneumonia in adults. After 1950, the proportion of pneumonia caused by pneumococcus began to decline. Pneumococcus has continued to decline; at present, this organism is identified in fewer than fewer10%–15% of cases. This proportion is higher in Europe, a finding likely related to differences in vaccination practices and smoking. Gram-negative bacilli, Staphylococcus aureus, Chlamydia, Mycoplasma, and Legionella are each identified in 2%–5% of patients with pneumonia who require hospitalization. Viruses are found in 25% of patients, up to one-third of these have bacterial coinfection. Recent studies fail to identify a causative organism in more than 50% of cases, which remains the most important challenge to understanding lower respiratory infection. Our findings have important implications for antibiotic stewardship and should be considered as new policies for empiric pneumonia management are developed.

21 December 2013 in CNS Drugs
Verified
Journal Article
Closed access
PDF file
MAMichael S. Abers
Michael S. Abers
WSWayne X. Shandera
Wayne X. Shandera
JKJoseph S. Kass
Joseph S. Kass

8 August 2021 in Immunology & Cell Biology
Verified
Journal Article
Open access
PDF file
MAMichael S Abers
Michael S Abers
LRLindsey B Rosen
Lindsey B Rosen
ODOttavia M Delmonte
Ottavia M Delmonte
ESElana Shaw
Elana Shaw
PBPaul Bastard
Paul Bastard
Michail LionakisMichail Lionakis
Michail Lionakis
Type‐I interferons (IFNs) mediate antiviral activity and have emerged as important immune mediators during coronavirus disease 19 (COVID‐19). Several lines of evidence suggest that impaired type‐I IFN signaling may predispose to severe COVID‐19. However, the pathophysiologic mechanisms that contribute to illness severity remain unclear. In this study, our goal was to gain insight into how type‐I IFNs influence outcomes in patients with COVID‐19. To achieve this goal, we compared clinical outcomes between 26 patients with neutralizing type‐I IFN autoantibodies (AAbs) and 192 patients without AAbs who were hospitalized for COVID‐19 at three Italian hospitals. The presence of circulating AAbs to type‐I IFNs was associated with an increased risk of admission to the intensive care unit and a delayed time to viral clearance. However, survival was not adversely affected by the presence of type‐I IFN AAbs. Our findings provide further support for the role of type‐I IFN AAbs in impairing host antiviral defense and promoting the development of critical COVID‐19 pneumonia in severe acute respiratory syndrome coronavirus 2‐infected individuals.

1 December 2019 in Trends in Molecular Medicine
Verified
Journal Article
Closed access
MAMichael S. Abers
Michael S. Abers
Michail LionakisMichail Lionakis
Michail Lionakis
DKDimitrios P. Kontoyiannis
Dimitrios P. Kontoyiannis